Trader’s Watch List: CEL-SCI Corporation (NYSEMKT:CVM), Schlumberger Limited (NYSE:SLB), Hovnanian Enterprises Inc. (NYSE:HOV), Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)

CEL-SCI Corporation (NYSEMKT:CVM) belongs to Healthcare sector. Its weekly performance is 9.23%. On last trading day company shares ended up $0.71. CEL-SCI Corporation (NYSEMKT:CVM) distance from 50-day simple moving average (SMA50) is -7.70%. On 1 July, CEL-SCI Corporation (NYSEMKT:CVM) announced that in June it has enrolled 25 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in just diagnosed, not yet treated patients with head and neck cancer. Total patient enrollment is now 488 as of June 30, 2015 in the world’s largest Phase 3 study in head and neck cancer.

Schlumberger Limited (NYSE:SLB) shares moved up 0.39% in last trading session and ended the day at $84.29. SLB Gross Margin is 23.00% and its return on assets is 7.20%. Schlumberger Limited (NYSE:SLB) quarterly performance is -3.71%. On 10 July, Schlumberger Limited (NYSE:SLB) announced that it has become the first service/supply contractor to voluntarily achieve SEMS certification to Center for Offshore Safety Program expectations.

On 13 July, Hovnanian Enterprises Inc. (NYSE:HOV) shares moved up 0.80% and was closed at $2.52. HOV EPS growth in last 5 year was 17.10%. Hovnanian Enterprises Inc. (NYSE:HOV) year to date (YTD) performance is -38.98%. Zacks downgraded shares of Hovnanian Enterprises Inc. (NYSE:HOV) from a hold rating to a sell rating in a research note released on Monday morning.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) ended the last trading day at $13.41. Company weekly volatility is calculated as 7.04% and price to cash ratio as 3.15. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) showed a weekly performance of -5.16%. On 1 July, Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced that on June 30, 2015, the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 115,500 shares of common stock to four new employees, with all four grants having a grant date of June 30, 2015 (the “Q2 2015 Inducement Grants”).

Leave a Reply

Your email address will not be published. Required fields are marked *